medigraphic.com
Instituto Nacional de Salud Pública

2010, Number 1

<< Back Next >>

salud publica mex 2010; 52 (1)

Biological, clinical and epidemiological aspects of latent tuberculosis

Barrios-Payán JA, Castañón-Arreola M, Flores-Valdez MA, Hernández-Pando R

Language: Spanish
References: 59
Page: 70-78
PDF size: 142.90 Kb.


ABSTRACT

Mycobacterium tuberculosis, the causal agent of tuberculosis, has affected humankind for approximately 20 000 years. Tuberculosis is a devastating disease, particularly in developing countries. One of its most notable characteristics is latent infection, in which live bacilli persist in the host tissues without clinical manifestations. Thus, the tuberculous bacilli adapt their metabolism to remain viable with low or no replication, avoiding their elimination by the immune system or conventional chemotherapy. Among the several problems that are particularly important to the understanding of this form of tuberculosis, and are not well-known, are the key metabolic steps that allow mycobacteria to remain in a dormant state and its interaction with host immunity. This article reviews some of the most significant biological, clinical and epidemiological aspects of this form of tuberculosis.


REFERENCES

  1. Daniel TM. The origins and precolonial epidemiology of tuberculosis in the Americas: can we figure them out? Int J Tuberc Lung Dis 2000;4:395-400.

  2. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, et al. Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 2006;8:2052-2060.

  3. Cardona PJ, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J 2004;24:1044-1051.

  4. Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, Harboe M, et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000;356:2133-2138.

  5. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004;84:29-44.

  6. World Health Organization. Global tuberculosis control: Surveillance, planning, financing.Genova: WHO, 2004.

  7. Opie E, Aronson J. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med 1927;4:21.

  8. Amberson J. The significance of latent forms of tuberculosis. N Engl J Med 1938;219:5.

  9. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998;6:107-112.

  10. Tuberculosis, TMACftEo. Latent tuberculosis infection: A guide for Massachusetts providers. Massachusetts, USA: The Medical Advisory Committee for the Elimination of Tuberculosis, 2005.

  11. Khomenko AG. The variability of Mycobacterium tuberculosis in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Tubercle 1987;68:243-253.

  12. Stanford JL. Much’s granules revisited. Tubercle 1987;68:241-242.

  13. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci U S A 2001;98:7534-7539.

  14. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006;13:179-186.

  15. Richeldi L, Ewer K, Losi M, Hansell DM, Roversi P, Fabbri LM, et al. Early diagnosis of subclinical multidrug-resistant tuberculosis. Ann Intern Med 2004;140:709-713.

  16. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-544.

  17. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996;64:2062-2069.

  18. Boon C, Dick T. Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy. J Bacteriol 2002;184:6760-6767.

  19. Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003;48:833-843.

  20. Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE 2008;3:e1502.

  21. Kumar A, Toledo JC, Patel RP, Lancaster JR, Steyn AJC. Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia sensor. Proc Natl Acad Sci 2007;104:11568-11573.

  22. Roupie V, Romano M, Zhang L, Korf H, Lin MY, Franken KLMC, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun 2007;75:941-949.

  23. Beste DJV, Laing E, Bonde B, Avignone-Rossa C, Bushell ME, McFadden JJ. Transcriptomic analysis identifies growth rate modulation as a component of the Adaptation of Mycobacteria to survival inside the macrophage. J Bacteriol 2007;189:3969-3976.

  24. Phyu S, Mustafa T, Hofstad T, Nilsen R, Fosse R, Bjune G. A mouse model for latent tuberculosis. Scand J Infect Dis 1998;30:59-68.

  25. McCune RM Jr, Tompsett R. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J Exp Med 1956;104:737-762.

  26. McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956;104:763-802.

  27. McCune RM, Feldmann FM, McDermott W. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966;123:469-486.

  28. Orme IM. A mouse model of the recrudescence of latent tuberculosis in the elderly. Am Rev Respir Dis 1988;137:716-718.

  29. Arriaga AK, Orozco EH, Aguilar LD, Rook GA, Hernandez-Pando R. Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin Exp Immunol 2002;128:229-237.

  30. Manabe YC, Kesavan AK, Lopez-Molina J, Hatem CL, Brooks M, Fujiwara R, et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) 2008;88:187-196.

  31. Kashino SS, Ovendale P, Izzo A, Campos-Neto A. Unique model of dormant infection for tuberculosis vaccine development. Clin Vaccine Immunol 2006;13:1014-1021.

  32. Capuano SV III, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, et al. Experimental Mycobacterium tuberculosis infection of Cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003;71:5831-5844.

  33. Society AT. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161:S221-S247.

  34. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-975.

  35. Codecasa L, Mantegani P, Galli L, Lazzarin A, Scarpellini P, Fortis C. An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection. J Clin Microbiol 2006;44:1944-1950.

  36. Fine PE, Bruce J, Ponnighaus JM, Nkhosa P, Harawa A, Vynnycky E. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 1999;3:962-975.

  37. Diagnostic standards and classification of tuberculosis in adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-1395.

  38. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol 2005;12:1311-1316.

  39. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of Tuberculin skin testing, QuantiFERON-TB Gold and T-SPOT.TB in Children. PLoS ONE 2008;3:e2624.

  40. Pai M, Zwerling A, Menzies-D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-184.

  41. Pottumarthy S, Morris AJ, Harrison AC, Wells VC. Evaluation of the Tuberculin Gamma Interferon Assay: potential to replace the Mantoux Skin Test. J Clin Microbiol 1999;37:3229-3232.

  42. van Pinxteren LAH, Ravn P, Agger EM, Pollock J, Andersen P. Diagnosis of Tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 2000;7:155-160.

  43. Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, Ayles H, et al. Rapid detection of active and latent tuberculosis infection in HIVpositive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. Aids 2002;16:2285-2293.

  44. Shi L, North R, Gennaro ML. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung. Infect Immun 2004;72:2420-2424.

  45. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28-106.

  46. Styblo K, Meijer J, Sutherland I. [The transmission of tubercle bacilli: its trend in a human population]. Bull World Health Organ 1969;41:137-178.

  47. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active Tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.

  48. Ponce-de-Leon A, Garcia-Garcia MdL, Garcia-Sancho MC, Gomez-Perez FJ, Valdespino-Gomez JL, Olaiz-Fernandez G, et al. Tuberculosis and diabetes in Southern Mexico. Diabetes Care 2004;27:1584-1590.

  49. Palomino JC, Leão SC, Ritacco V. Tuberculosis 2007 from basic science to patient care. Alemania: Amedeo Challenge, 2007.

  50. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827-830.

  51. Comstock GW, Woolpert SF. Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population. Arch Environ Health 1972;25:333-337.

  52. Hobby GL, Lenert TF. The in vitro action of antituberculous agents against multiplying and non-multiplying microbial cells. Am Rev Tuberc 1957;76:1031-1048.

  53. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966;123:445-468.

  54. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse events with 4 months of Rifampin therapy or 9 months of Isoniazid therapy for latent Tuberculosis infection: a randomized trial. Ann Intern Med 2008;149:689-697.

  55. Heifets L, Simon J, Pham V. Capreomycin is active against nonreplicating M. tuberculosis. Ann Clin Microbiol Antimicrob 2005;4:6.

  56. Hoff DR, Caraway ML, Brooks EJ, Driver ER, Ryan GJ, Peloquin CA, et al. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008;52: 4137-4140.

  57. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, Fornes P, Tailleux L, Barrios-Payan JA, et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS ONE 2006;1:e43

  58. Campuzano J, Aguilar D, Gonzalez-y Merchant J, Salas P, Espitia C, Hernández-Pando R. The PGRS domain of Mycobacterium tuberculosis. PEPGRS-Rv1759 is an efficient subunit vaccine to prevent reactivation in a murine model of chronic tuberculosis. Vaccine 2007; 25 (18): 3722-3729.

  59. Rook GAW, Lowry D, Hernández-Pando R. Immunotherapeutics for tuberculosis in experimental animals: Is there a common pathway activated by effective protocols? J Infect Dis 2007; 196: 191-198




2020     |     www.medigraphic.com